XML 54 R41.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Significant Agreements - Other Agreements (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Aug. 31, 2016 USD ($) item | Oct. 31, 2014 USD ($) shares | Aug. 31, 2014 USD ($) shares | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2017 USD ($)
Notes payable |  |  |  |  |  |  |  |  | $ 7,500
Research and development |  |  |  | $ 17,443 | $ 20,396 | $ 71,460 | $ 56,735 |  |
The General Hospital (MGH) | License Patent Rights |  |  |  |  |  |  |  |  |
Upfront fee |  |  | $ 100 |  |  |  |  |  |
Stock issued to licensors | shares |  |  | 66,848 |  |  |  |  |  |
Percentage of outstanding shares issued |  |  | 0.50% |  |  |  |  |  |
Research and development | $ 800 |  |  |  |  |  |  |  |
Market capitalization threshold | 1,000,000 |  |  |  |  |  |  |  |
Market capitalization |  |  |  |  |  |  |  |  | 1,000,000
The General Hospital (MGH) | Maximum | License Patent Rights |  |  |  |  |  |  |  |  |
Potential liability for future clinical, regulatory and commercial milestone payments related to product approval | 1,000 |  | $ 3,700 |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  | $ 1,800 |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval | $ 4,900 |  |  |  |  |  |  |  |
Percentage of net sales threshold for potential milestone payments to be made | 1.00% |  |  |  |  |  |  |  |
Number of licensed products | item | 4 |  |  |  |  |  |  |  |
Success Payments | $ 6,000 |  |  |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | License Patent Rights |  |  |  |  |  |  |  |  |
Upfront fee |  | $ 200 |  |  |  |  |  |  |
Stock issued to licensors | shares |  | 561,531 |  |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 License Agreement |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  | $ 16,500 |
License Agreement Contract Termination Term |  |  |  |  |  | 4 months |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cpf1 Market Cap Success Payments |  |  |  |  |  |  |  |  |
Notes payable payment terms |  |  |  |  |  | 150 days |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Cas9-II License Agreement |  |  |  |  |  |  |  |  |
Market capitalization |  |  |  |  |  |  |  |  | $ 1,000,000
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Maximum | Cpf1 License Agreement |  |  |  |  |  |  |  |  |
Royalties credit paid to third party (as a percent) |  |  |  |  |  | 50.00% |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Maximum | Cpf1 Success Payments |  |  |  |  |  |  |  |  |
Success Payments |  |  |  |  |  | $ 10,000,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Maximum | Cpf1 Market Cap Success Payments |  |  |  |  |  |  |  |  |
Success Payments |  |  |  |  |  | 125,000 |  |  |
Market capitalization threshold |  |  |  | 10,000,000 |  | 10,000,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Maximum | Cas9-II License Agreement |  |  |  |  |  |  |  |  |
Success Payments |  |  |  |  |  | 30,000 |  |  |
Market capitalization threshold |  |  |  | 9,000,000 |  | 9,000,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Minimum | Cpf1 Success Payments |  |  |  |  |  |  |  |  |
Success Payments |  |  |  |  |  | 750,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Minimum | Cas9-II License Agreement |  |  |  |  |  |  |  |  |
Market capitalization threshold |  |  |  | 1,000,000 |  | 1,000,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Rare disease | Maximum |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  | $ 36,000 |  |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | Rare disease | Maximum | Cpf1 License Agreement |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  | 36,000 |  | 36,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Maximum | License Patent Rights |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  | 14,800 |  |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Human disease | Maximum | Cpf1 License Agreement |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  | 20,000 |  | 20,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Human disease | Maximum | Cas9-II License Agreement |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  | 13,500 |  | 13,500 |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  |  |  |  |  | $ 3,700 |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Rare disease | Maximum | Cpf1 License Agreement |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  | 6,000 |  | 6,000 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States Europe And Japan | Rare disease | Maximum | Cas9-II License Agreement |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  |  |  | 9,000 |  | 9,000 |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  |  |  | $ 1,100 |  | $ 1,100 |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | United States and one other | Human disease | Maximum | License Patent Rights |  |  |  |  |  |  |  |  |
Potential liability for future clinical and regulatory milestone payments related to product approval |  | 4,100 |  |  |  |  |  |  |
Broad, Massachusetts Institute of Technology, or MIT, and Harvard (Institutions) | UNITED STATES | Human disease | Maximum | License Patent Rights |  |  |  |  |  |  |  |  |
Potential liability for future sales milestone payments |  | $ 54,000 |  |  |  |  |  |  |

X
- Definition Percentage of outstanding shares issued under collaboration agreement, which the reporting entity is obligated to maintain under the anti-dilution provisions of the agreement. + References No definition available. + Details
Name: | edit_CollaborationAgreementPercentageOutstandingSharesIssued
Namespace Prefix: | edit_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The potential liability for company's sale success payments. + References No definition available. + Details
Name: | edit_CompanySaleSuccessPaymentsUnderPatentRights
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the contract termination notice term under the license agreement. + References No definition available. + Details
Name: | edit_LicenseAgreementContractTerminationTerm
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of net revenue threshold for potential milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | edit_LicenseAgreementPercentageThresholdForPotentialMilestonePayments
Namespace Prefix: | edit_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of market capitalization. + References No definition available. + Details
Name: | edit_MarketCapitalization
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the market capitalization threshold under license agreement. + References No definition available. + Details
Name: | edit_MarketCapitalizationThreshold
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the payment terms for notes payable. + References No definition available. + Details
Name: | edit_NotesPayablePaymentTerms
Namespace Prefix: | edit_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of licensed products, in a research and clinical milestones. + References No definition available. + Details
Name: | edit_NumberOfLicensedProducts
Namespace Prefix: | edit_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents upfront payment fees to collaborators under agreements. + References No definition available. + Details
Name: | edit_PaymentsForUpfrontFeesToCollaborators
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of third party royalties that may be credited against the royalties due to counter party. + References No definition available. + Details
Name: | edit_PercentageOfRoyaltiesPaidCreditedTowardsRoyaltiesDue
Namespace Prefix: | edit_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate potential liability for future clinical, regulatory and commercial milestone payments related to product approval. + References No definition available. + Details
Name: | edit_PotentialLiabilityForClinicalRegulatoryAndCommercialMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate potential liability for future clinical and regulatory milestone payments related to product approval. + References No definition available. + Details
Name: | edit_PotentialLiabilityForProductApprovalClinicalAndRegulatoryMilestonePayments
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The potential liability for sales milestone payments. + References No definition available. + Details
Name: | edit_PotentialLiabilityForSalesMilestones
Namespace Prefix: | edit_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_NotesPayable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=edit_GeneralHospitalCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_LicensePatentRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=edit_HarvardBroadMitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cpf1LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cpf1MarketCapSuccessPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cas9IILicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=edit_Cpf1SuccessPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=edit_ProductForTreatmentOfRareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=edit_UnitedStatesEuropeAndJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=edit_ProductForTreatmentOfHumanDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=edit_UnitedStatesAndOneOtherLocationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |